The in vitro growth patterns and drug sensitivities of leukemic blast progenitors among the subtypes of acute myelocytic leukemia.
The in vitro growth activities and drug sensitivities of leukemic blast progenitors were compared among the subgroups of acute myelocytic leukemia (AML) classified according to the French-American-British (FAB) cooperative group. Leukemic cells separated from the peripheral bloods of AML patients were cultured in methylcellulose media, and the plating efficiencies of primary colonies (PE1) and secondary colonies after replating (PE2) were determined. PE1 and PE2 have been considered to reflect the capacities of terminal divisions and self-renewal of leukemic blast progenitors, respectively. PE1 and PE2 were variable among AML patients; these findings suggest that AML is a heterogeneous disease in terms of the proliferative activities of leukemic cells. No significant correlation was noted between PE1 or PE2 and the AML subtype. The sensitivities to cytosine arabinoside (Ara-C) of leukemic blast progenitors were studied in methylcellulose and suspension cultures. Ara-C sensitivity was not significantly correlated with the AML subtype, either. In contrast, there was statistically significant correlation between PE2 and the remission outcome of the patients, whereas PE1 was not significantly associated with the clinical outcome. The results in the present study indicate that the proliferative activity, especially self-renewal capacity, of leukemic blast progenitors is highly predictive of the prognosis of AML patients but is not significantly correlated with the AML subtype classified by the blast morphology.
Nara
N
N
Department of Laboratory Medicine, Tokyo Medical and Dental University, Japan.
Chen
G J
GJ
Murohashi
I
I
Tohda
S
S
Imai
Y
Y
Tomiyama
J
J
Nagata
K
K
Suzuki
T
T
Tanikawa
S
S
Shiina
S
S
D000293:Adolescent; D000328:Adult; D000368:Aged; D001752:Blast Crisis / Q000473:pathology; D002455:Cell Division / Q000187:drug effects; D003561:Cytarabine / Q000494:pharmacology; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000145:classification* / Q000473:pathology / Q000628:therapy; D012074:Remission Induction; D013234:Stem Cells / Q000473:pathology
D003561:Cytarabine